Multivariate analysis of DFS including potential risk factors and IKZF1 status in BCR-ABL1–positive ALL
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| EsPhALL good-risk (n = 62) | |||
| Age at diagnosis, years | |||
| <10 | 1 | ||
| ≥10 | 1.69 | 0.61-4.68 | .31 |
| WBC at diagnosis (× 109/L) | |||
| <50 | 1 | ||
| ≥50 | 1.53 | 0.62-3.78 | .36 |
| Imatinib exposure | |||
| Yes | 1 | ||
| No | 1.52 | 0.51-4.51 | .45 |
| IKZF1 status | |||
| Wild-type | 1 | ||
| Deleted | 4.30 | 0.98-19.0 | .05 |
| . | HR . | 95% CI . | P value . |
|---|---|---|---|
| EsPhALL good-risk (n = 62) | |||
| Age at diagnosis, years | |||
| <10 | 1 | ||
| ≥10 | 1.69 | 0.61-4.68 | .31 |
| WBC at diagnosis (× 109/L) | |||
| <50 | 1 | ||
| ≥50 | 1.53 | 0.62-3.78 | .36 |
| Imatinib exposure | |||
| Yes | 1 | ||
| No | 1.52 | 0.51-4.51 | .45 |
| IKZF1 status | |||
| Wild-type | 1 | ||
| Deleted | 4.30 | 0.98-19.0 | .05 |
For 62 of EsPhALL good-risk patients all covariates were known. EsPhALL-treated patients with a good early clinical response were stratified into the good-risk arm.
95% CI, 95% confidence interval; HR, hazard ratio; WBC, white blood cell count.